Log In Sign up
The largest database of trusted experimental protocols

Bigdye terminator v3 chemistry

Manufactured by Thermo Fisher Scientific
Visit Supplier

The BigDye™ Terminator v3 chemistry is a reagent system used for DNA sequencing. It provides the necessary components for carrying out the Sanger sequencing method, which is a widely used technique for determining the nucleotide sequence of DNA molecules.

Automatically generated - may contain errors

Lab products found in correlation

Seqscape software v2, by Thermo Fisher Scientific (5 mentions) 3730xl dna analyzer, by Thermo Fisher Scientific (5 mentions) Qiaamp dna mini and blood mini kit, by Qiagen (2 mentions) Qiaamp dna ffpe tissue kit, by Qiagen (2 mentions) Qiaamp dna blood mini kit, by Qiagen (1 mentions)

Spelling variants of this product

BigDye Terminator v3.1 (368 citations) BigDye Terminator (138 citations) BigDye v3.1 (94 citations) BigDye Terminator chemistry (67 citations) BigDye Terminator v3.1 sequencing chemistry (7 citations) BigDye Terminator v3.1 Cycle sequencing chemistry (5 citations) ABI BigDye Terminator chemistry (v3.1, (4 citations) BigDye Terminator v3.1 cycle sequencing kit chemistry (4 citations) ABI BigDye v3.1 dye terminator sequencing chemistry (2 citations)

5 protocols using bigdye terminator v3 chemistry

1

HER2 Gene Variant Screening in WBC

Check if the same lab product or an alternative is used in the 5 most similar protocols
Genomic DNA from 56 patients were isolated from white blood cell (WBC) fraction (also called buffy coat or PBMC) using a QIAamp DNA Blood Mini Kit (Qiagen, Germany). Then the region of interest of the five annotated single-nucleotide polymorphisms (SNPs) in the HER2 gene (−3444C>T, −1985 G>T, I655A A>G, P1170A C>G, rs1810132 STR C>T) was amplified using custom polymerase chain reaction (PCR) primers. Sanger sequencing was performed on a 3730xl DNA Analyzer (Applied Biosystems) using BigDye™ Terminator v3 chemistry (Applied Biosystems). Mutation analysis was performed using SeqScape®Software v2.5 (Applied Biosystems).
Falchook G.S., Moulder S., Naing A., Wheler J.J., Hong D.S., Piha-Paul S.A., Tsimberidou A.M., Fu S., Zinner R., Janku F., Jiang Y., Huang M., Parkhurst K.L, & Kurzrock R. (2014). A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Investigational new drugs, 33(1), 177-186.
+ Open protocol
+ Expand
2

Sanger Sequencing for Mutation Validation

Check if the same lab product or an alternative is used in the 5 most similar protocols
To confirm mutations found by Sequenom (see Results), the regions of interest were amplified using custom PCR primers. Sanger sequencing was performed on a 3730xl DNA Analyzer (Applied Biosystems) using BigDye Terminator v3 chemistry (Applied Biosystems). Mutation analysis was performed using SeqScape Software v2.5 (Applied Biosystems).
Mazumdar T., Byers L.A., Shing Ng P.K., Mills G.B., Peng S., Diao L., Fan Y.H., Stemke-Hale K., Heymach J.V., Myers J.N., Glisson B.S, & Johnson F.M. (2014). A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular cancer therapeutics, 13(11), 2738-2750.
+ Open protocol
+ Expand
3

Validation of Fusion Transcripts

Check if the same lab product or an alternative is used in the 5 most similar protocols
Validation of identified fusion transcripts was performed by PCR using custom primers for amplification. Sanger sequencing was performed on a 3730xl DNA Analyzer (Applied Biosystems) using BigDye™ Terminator v3 chemistry (Applied Biosystems). Fusion sequences were verified using BLAST (U.S. National Institutes of Health) and SeqScape Software v2.5 (Applied Biosystems).
Malouf G.G., Su X., Yao H., Gao J., Xiong L., He Q., Compérat E., Couturier J., Molinié V., Escudier B., Camparo P., Doss D.J., Thompson E.J., Khayat D., Wood C.G., Yu W., Teh B.T., Weinstein J, & Tannir N.M. (2014). Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(15), 4129-4140.
+ Open protocol
+ Expand
4

DNA Extraction and Sanger Sequencing for Mutation Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA was extracted from peripheral blood mononucleocytes (PBMCs) or paraffin-embedded tissue sections using the QIAamp® DNA Mini and Blood Mini Kit or QIAamp® DNA FFPE Tissue Kit (Qiagen, Valencia, CA) according to standard protocols recommended by the manufacturer. The region of interest was then amplified using custom PCR primers. Sanger sequencing was performed on a 3730xl DNA Analyzer (Applied Biosystems) using BigDye™ Terminator v3 chemistry (Applied Biosystems). Mutation analysis was performed using SeqScape® Software v2.5 (Applied Biosystems).
Falchook G.S., Wheler J.J., Naing A., Piha-Paul S.A., Fu S., Tsimberidou A.M., Hong D.S., Janku F., Zinner R., Jiang Y., Huang M., Lin Q., Parkhurst K, & Kurzrock R. (2014). Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Investigational new drugs, 33(1), 215-224.
+ Open protocol
+ Expand
5

Sanger Sequencing of Genomic DNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
DNA was extracted from peripheral blood mononucleocytes (PBMCs) or paraffin-embedded tissue sections using the QIAamp® DNA Mini and Blood Mini Kit or QIAamp® DNA FFPE Tissue Kit (Qiagen, Valencia, CA) according to standard protocols recommended by the manufacturer. The region of interest was then amplified using custom PCR primers. Sanger sequencing was performed on a 3730xl DNA Analyzer (Applied Biosystems) using BigDye™ Terminator v3 chemistry (Applied Biosystems). Mutation analysis was performed using SeqScape® Software v2.5 (Applied Biosystems).
Falchook G.S., Wheler J.J., Naing A., Jackson E.F., Janku F., Hong D., Ng C.S., Tannir N.M., Lawhorn K.N., Huang M., Angelo L.S., Vishwamitra D., Hess K., Howard A.N., Parkhurst K.L., Amin H.M, & Kurzrock R. (2014). Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget, 5(21), 10280-10292.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!